Role of radiotherapy fractionation in head and neck cancers (MARCH): an updated meta-analysis.

[1]  M. Parmar,et al.  What is the most effective treatment for head and neck squamous cell carcinoma? An individual patient data network meta-analysis from the MACH-NC and MARCH collaborative groups , 2017 .

[2]  J. Pignon,et al.  Bias and precision of methods for estimating the difference in restricted mean survival time from an individual patient data meta-analysis , 2016, BMC Medical Research Methodology.

[3]  J. Pignon,et al.  Difference in Restricted Mean Survival Time for Cost-Effectiveness Analysis Using Individual Patient Data Meta-Analysis: Evidence from a Case Study , 2016, PloS one.

[4]  P. Pai,et al.  Conventional radiotherapy versus concurrent chemoradiotherapy versus accelerated radiotherapy in locoregionally advanced carcinoma of head and neck: Results of a prospective randomized trial , 2016, Head & neck.

[5]  C. Rasch,et al.  Induction chemotherapy with docetaxel/cisplatin/5-fluorouracil followed by randomization to two cisplatin-based concomitant chemoradiotherapy schedules in patients with locally advanced head and neck cancer (CONDOR study) (Dutch Head and Neck Society 08-01): A randomized phase II study. , 2016, European journal of cancer.

[6]  venlig hilsen,et al.  Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck : DAHANCA 6 and 7 randomised controlled trial , 2016 .

[7]  T. Björk-Eriksson,et al.  Mature results from a Swedish comparison study of conventional versus accelerated radiotherapy in head and neck squamous cell carcinoma - The ARTSCAN trial. , 2015, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[8]  Patrick Royston,et al.  Meta‐analysis of time‐to‐event outcomes from randomized trials using restricted mean survival time: application to individual participant data , 2015, Statistics in medicine.

[9]  Jun Ma,et al.  Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis. , 2015, The Lancet. Oncology.

[10]  Christopher U. Jones,et al.  Randomized trial of hyperfractionation versus conventional fractionation in T2 squamous cell carcinoma of the vocal cord (RTOG 9512). , 2014, International journal of radiation oncology, biology, physics.

[11]  Christopher U. Jones,et al.  Final results of local-regional control and late toxicity of RTOG 9003: a randomized trial of altered fractionation radiation for locally advanced head and neck cancer. , 2014, International journal of radiation oncology, biology, physics.

[12]  E. Chung,et al.  A prospective randomized trial comparing hypofractionation with conventional fractionation radiotherapy for T1-2 glottic squamous cell carcinomas: results of a Korean Radiation Oncology Group (KROG-0201) study. , 2014, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[13]  K. Ramadas,et al.  Phase 2B Randomized Trial Comparing Concurrent Chemoradiation to 6 Fractions/Week Accelerated Radiation Therapy in Advanced Squamous Cell Carcinomas of Head and Neck , 2013 .

[14]  J. Overgaard,et al.  DAHANCA 9: a randomized multicenter study to compare accelerated normo-fractionated radiotherapy with accelerated hyperfractionated radiotherapy in patients with primary squamous cell carcinoma of the head and neck , 2013 .

[15]  Pierre Blanchard,et al.  Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  I. Chitapanarux,et al.  Randomized phase III trial of concurrent chemoradiotherapy vs accelerated hyperfractionation radiotherapy in locally advanced head and neck cancer , 2013, Journal of radiation research.

[17]  Suresh C. Sharma,et al.  Comparison of concomitant boost radiotherapy against concurrent chemoradiation in locally advanced oropharyngeal cancers: a phase III randomised trial. , 2013, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[18]  V. Grégoire,et al.  Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): an open-label phase 3 randomised trial. , 2012, The Lancet. Oncology.

[19]  J F Tierney,et al.  A critical review of methods for the assessment of patient-level interactions in individual participant data meta-analysis of randomized trials, and guidance for practitioners. , 2011, Journal of clinical epidemiology.

[20]  K. Ang,et al.  Human papillomavirus and survival of patients with oropharyngeal cancer. , 2010, The New England journal of medicine.

[21]  C. Grau,et al.  Five versus six fractions of radiotherapy per week for squamous-cell carcinoma of the head and neck (IAEA-ACC study): a randomised, multicentre trial. , 2010, The Lancet. Oncology.

[22]  C. Leemans,et al.  Postoperative accelerated radiotherapy (POPART) versus conventional postoperative radiotherapy (CPORT) in squamous cell head and neck cancer: A multicenter prospective randomized study of the Dutch Head and Neck Cooperative Study Group. , 2010 .

[23]  M. Parmar,et al.  Mature results of a randomized trial of accelerated hyperfractionated versus conventional radiotherapy in head-and-neck cancer. , 2010, International journal of radiation oncology, biology, physics.

[24]  J. Pignon,et al.  Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[25]  S. Sharma,et al.  Concomitant boost radiotherapy compared with conventional radiotherapy in squamous cell carcinoma of the head and neck--a phase III trial from a single institution in India. , 2008, Clinical oncology (Royal College of Radiologists (Great Britain)).

[26]  B. Maciejewski,et al.  Randomized clinical trial on 7-days-a-week postoperative radiotherapy for high-risk squamous cell head and neck cancer. , 2007, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[27]  P. Warde,et al.  Five year results of a randomized trial comparing hyperfractionated to conventional radiotherapy over four weeks in locally advanced head and neck cancer. , 2007, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[28]  J. Langendijk.  The dutch head and neck cancer cooperative study group (NWHHT-SG) , 2007 .

[29]  M. Tsukuda,et al.  Comparison of hyperfractionation and conventional fractionation radiotherapy with concurrent docetaxel, cisplatin and 5-fluorouracil (TPF) chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN) , 2007, Cancer Chemotherapy and Pharmacology.

[30]  B. Maciejewski,et al.  Continuous accelerated 7-days-a-week radiotherapy for head-and-neck cancer: long-term results of phase III clinical trial. , 2006, International journal of radiation oncology, biology, physics.

[31]  Brian O'Sullivan,et al.  Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis , 2006, The Lancet.

[32]  J. Bourhis,et al.  Phase III randomized trial of very accelerated radiation therapy compared with conventional radiation therapy in squamous cell head and neck cancer: a GORTEC trial. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  V. Krstevska,et al.  Altered and conventional fractionated radiotherapy in locoregional control and survival of patients with squamous cell carcinoma of the larynx, oropharynx, and hypopharynx. , 2006, Croatian medical journal.

[34]  H. Yamazaki,et al.  Radiotherapy for early glottic carcinoma (T1N0M0): results of prospective randomized study of radiation fraction size and overall treatment time. , 2006, International journal of radiation oncology, biology, physics.

[35]  T. Shouman,et al.  A randomized study of accelerated fractionation radiotherapy with and without mitomycin C in the treatment of locally advanced head and neck cancer. , 2005, Journal of the Egyptian National Cancer Institute.

[36]  M. Sormani,et al.  Accelerated versus conventional fractionated postoperative radiotherapy for advanced head and neck cancer: results of a multicenter Phase III study. , 2003, International journal of radiation oncology, biology, physics.

[37]  Cai Grau,et al.  Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6&7 randomised controlled trial , 2003, The Lancet.

[38]  V. Torri,et al.  Locoregionally advanced carcinoma of the oropharynx: conventional radiotherapy vs. accelerated hyperfractionated radiotherapy vs. concomitant radiotherapy and chemotherapy--a multicenter randomized trial. , 2003, International journal of radiation oncology, biology, physics.

[39]  G. Noël,et al.  Alternating chemoradiotherapy versus partly accelerated radiotherapy in locally advanced squamous cell carcinoma of the head and neck: results from a phase III randomized trial , 2002 .

[40]  S. Thompson,et al.  Quantifying heterogeneity in a meta‐analysis , 2002, Statistics in medicine.

[41]  H. Bartelink,et al.  Concomitant cisplatin and radiotherapy in a conventional and modified fractionation schedule in locally advanced head and neck cancer: a randomised phase II EORTC trial. , 2002, European journal of cancer.

[42]  A. Begg,et al.  Accelerated hyperfractionation (AHF) compared to conventional fractionation (CF) in the postoperative radiotherapy of locally advanced head and neck cancer: influence of proliferation , 2002, British Journal of Cancer.

[43]  A. Serafin,et al.  A multicentre randomized/controlled trial of a conventional versus modestly accelerated radiotherapy in the laryngeal cancer: influence of a 1 week shortening overall time. , 2002, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[44]  L. Peters,et al.  A randomised trial of accelerated and conventional radiotherapy for stage III and IV squamous carcinoma of the head and neck: a Trans-Tasman Radiation Oncology Group Study. , 2002, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[45]  A. Garden,et al.  Randomized trial addressing risk features and time factors of surgery plus radiotherapy in advanced head-and-neck cancer. , 2002, International journal of radiation oncology, biology, physics.

[46]  J. Naude,et al.  Continuous hyperfractionated accelerated radiotherapy with/without mitomycin C in head and neck cancers. , 2000, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[47]  Robert Gray,et al.  A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .

[48]  W. Millesi,et al.  Continuous hyperfractionated accelerated radiotherapy with/without mitomycin C in head and neck cancer. , 1998, International journal of radiation oncology, biology, physics.

[49]  C. Lengeler,et al.  Language bias in randomised controlled trials published in English and German , 1997, The Lancet.

[50]  J. Horiot,et al.  Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers: results of the EORTC 22851 randomized trial. , 1997, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[51]  L. Weir,et al.  A randomised trial of accelerated versus conventional radiotherapy in head and neck cancer. , 1997, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[52]  M Schemper,et al.  A note on quantifying follow-up in studies of failure time. , 1996, Controlled clinical trials.

[53]  Mike Clarke,et al.  EFFECTS OF RADIOTHERAPY AND SURGERY IN EARLY BREAST-CANCER - AN OVERVIEW OF THE RANDOMIZED TRIALS , 1995 .

[54]  Anthony Howell,et al.  Effects of radiotherapy and surgery in early breast cancer. An overview of the randomized trials. , 1995, The New England journal of medicine.

[55]  L. Stewart,et al.  Practical methodology of meta-analyses (overviews) using updated individual patient data. Cochrane Working Group. , 1995, Statistics in medicine.

[56]  O. Brodin,et al.  Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials , 1995 .

[57]  D. Arthur,et al.  42 Standard once-daily versus thrice-daily concomitant boost accelerated superfractionated irradiation for advanced squamous cell carcinoma of the head and neck: Preliminary results of a prospective randomized trial , 1995 .

[58]  K. Dickersin,et al.  Publication Bias: The Problem That Won't Go Away , 1993, Annals of the New York Academy of Sciences.

[59]  M. Parmar,et al.  Meta-analysis of the literature or of individual patient data: is there a difference? , 1993, The Lancet.

[60]  H. Awwad,et al.  Accelerated versus conventional fractionation in the postoperative irradiation of locally advanced head and neck cancer: influence of tumour proliferation. , 1992, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[61]  S Schraub,et al.  Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: final analysis of a randomized trial of the EORTC cooperative group of radiotherapy. , 1992, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[62]  Mike Clarke,et al.  Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women , 1992 .

[63]  Anthony Howell,et al.  Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group. , 1992 .

[64]  Early Breast Cancer Trialists' Collaborative Group.  Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women , 1992, The Lancet.

[65]  A. D. Schryver,et al.  Systemic treatment of early breast-cancer by hormonal, cytotoxic, or immune therapy: 133 randomized trials involving 31000 recurrences and 24000 deaths among 75000 women: 1 , 1992 .

[66]  L. Souhami,et al.  Prospective randomized trial comparing hyperfractionated versus conventional radiotherapy in stages III and IV oropharyngeal carcinoma. , 1991, International journal of radiation oncology, biology, physics.

[67]  T. Pajak,et al.  Hyperfractionated photon radiation therapy in the treatment of advanced squamous cell carcinoma of the oral cavity, pharynx, larynx, and sinuses, using radiation therapy as the only planned modality: (preliminary report) by the Radiation Therapy Oncology Group (RTOG). , 1987, International journal of radiation oncology, biology, physics.

[68]  R. Peto,et al.  Beta blockade during and after myocardial infarction: an overview of the randomized trials. , 1985, Progress in cardiovascular diseases.